Ultime notizie per CG Oncology (NASDAQ:CGON) Azioni

CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology Inc

EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), the world's leading Urban Air Mobility ("UAM") technology platform company, today announced that it has signed a cooperation framework agreement ("Agreement") with Zhejiang Sunriver Culture and Tourism Co., Ltd. ("Sunriver", 600576.SH), a China A-share listed company, to explore an industrial model that integrates low-altitude economy with cultural tourism in China. Under the Agreement, Sunriver plans to purchase 50 units of EH216-S or similar pilotless passenger-carrying aircraft from EHang for its cultural tourism projects based on market development needs. Sunriver has placed a purchase order for 5 units of EH216-S as the first batch for aerial tourism use cases. The remaining aircraft will be gradually deployed in the tourism attractions under the Sunriver.

News

Contracts

Global

EHang Partners with Sunriver To Expand Chinese Cultural Tourism Market With Purchase Plan For 50 Units Of EH216-S Or Similar Pilotless Passenger-Carrying Aircraft From EHang For Its Cultural Tourism Projects Based On Market Development Needs

Suburban Propane Partners, L.P. (NYSE:<a href="https://www.benzinga.com/stock/SPH#NYSE">SPH</a>), a nationwide distributor of propane, renewable propane, renewable natural gas, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, announced today an executive promotion in line with its planned management succession. As previously announced, Steven C. Boyd, the Partnership's Chief Operating Officer, will retire effective January 1, 2025.
The Partnership announced that Alejandro ("Alex") Centeno has been promoted to Senior Vice President – Operations as successor to Mr. Boyd. In his role, Mr.&nbsp;Centeno will report to Michael A. Stivala, President and Chief Executive Officer. Mr.&nbsp;Centeno has been with the Partnership for over 15 years, where he has held several managerial positions within the operations, most recently, rising to the level of Vice President – Operations since August 2023. In his new position, Mr.&nbsp;Centeno will be responsible for leading all aspects of the day-to-day operations of the propane business, as well as advancing the Partnership's customer base growth and retention initiatives, driving continued improvements in operational efficiencies and overseeing operational support functions; including safety, marketing and fleet management.&nbsp;

Management

Suburban Propane Partners, L.P.'s Steven C. Boyd, The Partnership's Chief Operating Officer, Will Retire Effective January 1, 2025; Alejandro ("Alex") Centeno Has Been Promoted To Senior Vice President – Operations As Successor To Mr. Boyd

Benchmark analyst Daniel Kurnos maintains Cineverse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>) with a Speculative Buy and raises the price target from $9 to $10.

Price Target

Analyst Ratings

CNVS

Benchmark Maintains Speculative Buy on Cineverse, Raises Price Target to $10

AKAM

Akamai Is The Winning Bidder To Acquire Select Assets From Edgio, Including Customer Contracts From Edgio's Businesses In Security And Content Delivery, And Non-Exclusive License Rights To Edgio's Entire Patent Portfolio

WIIM

IFRX

InflaRx shares are trading higher after the company announced CHMP of the European Medicines Agency recommended the marketing authorization of Gohibic for the treatment of adult patients with Sars-cov-2-inducted acute respiratory distress syndrome.

Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) reported quarterly losses of $(1.29) per share. This is a 78.36 percent increase over losses of $(5.96) per share from the same period last year. The company reported $7.53 million in sales this quarter. This is a 29.81 percent increase over sales of $5.80 million the same period last year.

Earnings

SLNH

Soluna Holdings Q3 EPS $(1.29) Up From $(5.96) YoY, Sales $7.53M Up From $5.80M YoY

MAMO

Massimo Group Q3 EPS $(0.06) Down From $(0.10) YoY; Revenue $25.6M Down From $29.9M YoY

Benchmark analyst Josh Sullivan maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Buy and raises the price target from $10 to $16.

LUNR

Benchmark Maintains Buy on Intuitive Machines, Raises Price Target to $16

Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares are declining premarket on Friday. Yesterday, the company disclosed a securities purchase agreement to sell 16 million shares of common stock at $2.50 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41999265/quantum-computing-inc-announces-registered-direct-offering-of-40-million-priced-at-the-market-unde" rel="noreferrer noopener">per share in a registered direct offering</a>.
The company expects to generate gross proceeds of $40 million. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around November 18, 2024, pending customary closing conditions.
The company plans to use the net proceeds from the offering for debt repayment, working capital, and general corporate purposes.
This week, the company announced its first secured order for thin film lithium niobate (TFLN) photonic chip technology,<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/41953419/quantum-computing-shares-are-up-by-more-than-70-heres-what-you-need-to-know" rel="noreferrer noopener"> marking a milestone for its foundry services</a>.
This month, Quantum Computing reported third-quater GAAP loss per share of $0.06, an improvement from a loss of $0.10 year-over-year. However, sales totaled $101,000, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41786575/quantum-computing-inc-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">missing the $300,000 estimate</a>.
Price Action: QUBT shares are down 30.9% at $3.04 premarket at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42006281" target="_blank" rel="noreferrer noopener">Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments</a></li>
</ul>

Equities

Offerings

Small Cap

Movers

QUBT

Quantum Computing Dives After $40M Stock Offering - What's Going On?

Intends to vote FOR shareholder nominees and AGAINST re-election of incumbents, including Nano Dimension CEO Yoav Stern
Intends to vote FOR shareholder proposal to declassify Nano Dimension Board of Directors
Intends to vote AGAINST CEO Stern's egregious compensation package
TORONTO, Nov. 15, 2024 /PRNewswire/ -- Anson Advisors Inc. and Anson Funds Management LP, the co-investment advisers of several investment funds (collectively, the "Anson Funds"), the largest shareholder of Nano Dimension Ltd. ("Nano Dimension" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>), today announced its intention to vote FOR all shareholder nominees and a shareholder proposal to declassify the Board of Directors at Nano Dimension's upcoming 2024 Annual General Meeting of Shareholders to be held on December 6, 2024. Anson Funds also intends to vote AGAINST Nano Dimension CEO Yoav Stern's egregious compensation package.&nbsp;
Anson Funds continues to believe that the incumbent Board of Directors has failed to provide sufficient oversight over Mr. Stern, allowing him to continue acquiring cash-burning entities despite a track record of poor results. Following a thorough review of the Company's proxy materials, as well as those published by the dissident, we believe a refreshed Board with independent directors combined with the proposed governance enhancements represent a critical first step to ending the persistent and ongoing value destruction at Nano Dimension.
&nbsp;

NNDM

Anson Funds To Vote For All Shareholder Nominees And Proposals At Nano Dimension's Upcoming Annual General Meeting; Intends To Vote FOR Shareholder Nominees And AGAINST Re-Election Of Incumbents, Including Nano Dimension CEO Yoav Stern

AIM ImmunoTech shares are trading higher after the company reported better-than-expected Q3 EPS results.

Benchmark analyst Fawne Jiang maintains Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) with a Buy and raises the price target from $16 to $24.

BILI

Benchmark Maintains Buy on Bilibili, Raises Price Target to $24

POLA

Polar Power shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Macro Economic Events

Retail Sales

Econ #s

Economics

US Core Retail Sales (MoM) (Oct)	+0.1% vs +0.3% Est.; Prior +1%

USA Import Price Index (MoM) For Oct. 0.3% Vs -0.1% Est.; -0.4% Prior

VRAR

The Glimpse Group shares are trading higher. The company reported Q1 financial results.

USA Export Price Index (MoM) For Oct. 0.8% Vs -0.1% Est.; -0.6% Prior

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported better-than-expected fourth-quarter results after <a href="https://www.benzinga.com/quote/AMAT/earnings">Thursday&#8217;s closing bell</a>.
Applied Materials reported quarterly earnings of $2.32 per share, which beat the analyst consensus estimate of $2.19. Quarterly revenue clocked in at $7.05 billion, which beat the analyst consensus estimate of $6.95 billion and is an increase over sales of $6.72 billion from the same period last year.
"Applied Materials' technology leadership and strong execution drove record Q4 and fiscal 2024 performance, our fifth consecutive year of growth," said Gary Dickerson, president and CEO.
For the first quarter of fiscal 2025, Applied expects net revenue to be approximately $7.15 billion, plus or minus $400 million. Non-GAAP diluted EPS is expected to be approximately $2.29, plus or minus 18 cents.
Applied shares gained 1.8% to close at $186.00 on Thursday.
These analysts made changes to their price targets on Applied Materials following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60ed6112b473c600014bf1c9/charles-shi">Needham analyst Charles Shi</a> maintained the stock with a Buy and lowered the price target from $240 to $225.</li>
<li>Deutsche Bank analyst Sidney Ho maintained the stock with a Hold and lowered the price target from $220 to $200.</li>
<li>Morgan Stanley analyst Joseph Moore maintained Applied Materials with an Equal-Weight rating and cut the price target from $185 to $179.</li>
<li>B of A Securities analyst Vivek Arya maintained the stock with a Buy and lowered the price target from $220 to $210.</li>
<li>Wells Fargo analyst Joseph Quatrochi maintained the stock with an Overweight and lowered the price target from $235 to $220.</li>
</ul>
Considering buying AMAT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15082856/image-172-1024x534.png" alt="" class="wp-image-650222" style="width:748px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15082856/image-172-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15082856/image-172-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15082856/image-172-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15082856/image-172.png 1212w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

AMAT

These Analysts Slash Their Forecasts On Applied Materials Following Q4 Earnings

US Retail Sales Month Over Month (Oct) +0.4% vs +0.3% Est.; Prior +0.8%

In the current session, the stock is trading at $62.00, after a 0.56% increase. Over the past month, Sabine Royalty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBR#NYSE">SBR</a>) stock increased by 0.19%, and in the past year, by 0.70%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731677414_0.png" alt="Past Year Chart" />

<h3>Evaluating Sabine Royalty P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 22.62 in the Oil, Gas &amp; Consumable Fuels industry, Sabine Royalty Inc. has a lower P/E ratio of 10.16. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731677414_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Sabine Royalty

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated price target ...

Buy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market Prospects

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associate...

Optimistic Outlook for CG Oncology as Trial Cessation Boosts Cretostimogene Prospects

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $86....

Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market Opportunities

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target...

Promising Prospects for CG Oncology, Inc.: Buy Rating Reinforced by Positive MIBC Treatment Outcomes and Market Opportunities

CG Oncology, Inc. GAAP EPS of -$0.30

CG Oncology, Inc. ( ($CGON) ) has released its Q3 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors. CG...

CG Oncology's Financial Results and Clinical Developments

ALMS

AMGN

AZNCF

BMYMP

BPMC

CATX

CGEM

CGON

ELYM

GLAXF

HAFC

IDYA

IMCR

INCY

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

General

CADL

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

Health Care

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

CG Oncology

Notizie

Ultime notizie per CG Oncology (NASDAQ:CGON) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO